Imunon Inc (IMNN)vsRevolution Medicines Inc (RVMD)
IMNN
Imunon Inc
$1.47
+1.38%
HEALTHCARE · Cap: $8.75M
RVMD
Revolution Medicines Inc
$203.77
+0.21%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Revolution Medicines Inc generates 494% more annual revenue ($742,000 vs $125,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
IMNN
Avoid23
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 16.8x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : IMNN
IMNN has a balanced fundamental profile.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : IMNN
The primary concerns for IMNN are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 1.87 is elevated, increasing financial risk.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
IMNN carries more volatility with a beta of 1.97 — expect wider price swings.
IMNN is growing revenue faster at 0.0% — sustainability is the question.
RVMD generates stronger free cash flow (-745M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVMD scores higher overall (24/100 vs 23/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Imunon Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Imunon Inc. is a clinical-stage biotechnology company at the forefront of developing innovative immune-mediated therapies targeting cancer and infectious diseases. Leveraging its proprietary INFECT platform, Imunon aims to enhance immune response mechanisms, facilitating effective tumor eradication. With a diversified pipeline of therapeutics across multiple clinical stages and strategic collaborations that bolster its operational expertise, Imunon is strategically positioned to revolutionize immunotherapy, offering the potential to significantly enhance treatment outcomes for patients while shaping the future of the biopharmaceutical landscape.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?